EGFR and neoplasm: The potential of complement targeting by nanobody fusion proteins was explored by Pedersen et al., who directed complement activation to tumor cells by combining hFPNb1 with a nanobody targeting the epidermal growth factor receptor expressed on cancer cells [123].